ClinicalTrials.gg
RecruitingNCT05901688ULOOPUpdated Mar 12, 2024

Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes

An observational study in Small for Gestational Age at Delivery, Hypoxic-Ischemic Encephalopathy and Stillbirth, sponsored by Medway NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Medway NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
16 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom — 3 open to participants now, 5 under way, none of them phase 3. Hypoxia-Ischemia, Brain · United Kingdom.

Started
2023
with 1 other
Observational
8 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
Medway NHS Foundation Trust

Among the 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 15th registered.

Hypoxia-Ischemia, Brain

261 studies on the registry are indexed under Hypoxia-Ischemia, Brain; 93 are open to participants now.

Browse Hypoxia-Ischemia, Brain studies →

Open to participants now

3 of the 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 59 Hypoxia-Ischemia, Brain studies recruiting now, 21 (36%) set no upper age limit and 36 (61%) stop at 75 or younger; 46 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hypoxia-Ischemia, Brain with a site in United Kingdom, or all of them as a file.
02

Study summary

The objective of our study is to investigate the association of umbilical cord abnormalities with adverse pregnancy outcomes. The umbilical cord parameters that will be investigated as part of this study include the umbilical cord coiling index (UCI), umbilical cord (UC) diameter, umbilical vein (UV) diameter, UV flow velocity and the presence of nuchal cord. The UCI, UC, UV diameter \& flow and presence of nuchal cord will be measured in routine unselected populations at 20-22 weeks and 35-37 weeks gestation during the study period. We will also measure the UC and UV diameter in a nested population of high-risk pregnancies attending our placental disorders clinic which have been deemed to be at risk of having adverse pregnancy outcomes.

Primary objective:

To investigate if prenatal assessment of UCI, UC, UV diameter \& flow and presence of nuchal cord measured routinely in unselected screened populations at 20-22 weeks and 35-37 weeks' can provide an independent prediction of pregnancies that develop adverse pregnancy outcomes.

Secondary objectives:

To assess the correlation of UC and UV diameter measured by ultrasound scan and fetal magnetic resonance imaging in prediction of pregnancy outcome. To examine the association of these umbilical cord measurements and observations in a nested cohort of pregnancies in the high-risk placental disorders clinic.

Read the detailed description

The umbilical diameter is less than 2 cm, grows to a length of 50-60 cm by 28 weeks gestation and contains around 40 helical turns, which are twisted to the left rather than right because of the arrangement of helical muscle fibers in the vessels of the umbilical cord. These twists in the umbilical cord add to the strength of the cord by providing protection and resistance against compression of umbilical vessels. The overall final length of the UC and the number of coils is thought to be determined by the tensile forces due to fetal movements, rate of growth of UA and UV, fetal hemodynamics, distribution of the muscle fibers in the UA and amniotic fluid volume.

One of the common causes of fetal and neonatal adverse outcomes such as stillbirths or hypoxic ischaemic encephalopathy (HIE) is fetal hypoxia. The optimally oxygenated blood is transferred from the maternal blood to the fetus, crossing the placenta and the UC to reach fetal circulation. There are several studies which demonstrate that fetal hypoxia due to placental causes, whether chronic or acute, can lead to reduced transfer of oxygen and nutrition to the fetus. There is evidence from clinical and histological studies that impaired trophoblastic proliferation causes impaired placentation and leads to reduced oxygen transfer to the fetus resulting in preeclampsia (PE), fetal growth restriction (FGR) or stillbirth. However, there is limited and uncertain evidence regarding the contribution of UC abnormalities in the prediction of pregnancies with fetal hypoxia that result in hypoxic adverse outcomes such as HIE and stillbirth. There is need for further research to investigate the causes related to UC as not all hypoxic adverse outcomes have a placental etiology and a significant proportion of pregnancies with FGR, stillbirth and HIE have no ultrasound or histological evidence of impaired placentation, suggesting that there may be other factors in addition to the placenta that lead to such hypoxic morbidity.

There are studies published in literature demonstrating an association between UC abnormalities and adverse pregnancy outcomes such as FGR, PE, stillbirth or adverse outcomes such as caesarean section (CS) for fetal distress; but many of these are postnatal studies based on morphological and histological examination rather than prospective cohort studies carried out in the antenatal period. The few studies that investigate UC abnormalities in prenatal period are retrospective case-control studies with a relatively small sample size. This makes the findings less generalizable and overall difficult to effectively assess the precise contribution of UC abnormalities detected on ultrasound in the prenatal period that can potentially improve management and prevent such adverse outcomes.

This is a prospective observational cohort study carried out at a single center. This study will be conducted in compliance with the study protocol, the Declaration of Helsinki (1996), the principles of Good Clinical Practice (GCP) and applicable regulatory requirements. The study will be reviewed and approved by the Research Ethics Committees (REC) and competent authorities.

At our centre, all women booked for their maternity care are offered 3 routine ultrasound scans in their pregnancy: 11-13 weeks', 20-22 weeks' and at 35-37 weeks' gestation. Pregnancies that are deemed to be at high risk for delivery of a small for gestational age neonate are referred to a specialist placental disorders clinic for closer antenatal monitoring and fetal surveillance. At these visits, we ensure that there is a complete record of their personal, medical and obstetric history and perform an ultrasound scan to assess fetal growth, amniotic fluid and Doppler studies. This prospective study has two parts: first, a prospective observational cohort study in an unselected population and a nested cohort study in a high-risk population. Those agreeing to take part will be offered a patient information sheet and requested to sign a consent form, confirming their willingness to participate.

Prospective cohort study: In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:

  1. Umbilical cord coiling index (UCI)
  2. Transverse diameter of umbilical cord (UC)
  3. Transverse diameter of umbilical vein (UV) and artery (UA)
  4. Umbilical vein (UV) Doppler flow characteristics
  5. Presence of nuchal cord

Nested cohort study: In the nested cohort study of the high-risk pregnancies, women are offered measurement of fetal biometry and Doppler assessments including UA Doppler as part of the standard care. Women will be invited to take part in the study which will involve taking the following additional ultrasound measurements:

  1. Umbilical cord coiling index (UCI)
  2. Transverse diameter of umbilical cord (UC)
  3. Transverse diameter of umbilical vein (UV) and artery (UA)
  4. Umbilical vein (UV) Doppler flow characteristics

The additional measurements of UC, UV and nuchal cord will only add 2-3 minutes of examination time and will not affect the care of women attending for their routine assessments as well as in the high-risk placental disorders clinic. These measurements taken as part of the study will not be available for clinical management and will be analysed after the completion of the study period.

03

Conditions studied

  • Small for Gestational Age at Delivery
  • Hypoxic-Ischemic Encephalopathy
  • Stillbirth
  • Admission to Neonatal Unit
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will be carried out in two cohorts: the first is the cohort of unselected population of pregnancies attending for their routine pregnancy care and ultrasound appointments at 20-22 weeks and 35-37 weeks. A nested cohort study will also be carried out in a high-risk cohort of pregnancies referred to the placental disorders clinic for women who have risk factors for delivering a small for gestational age baby or those at risk of developing preeclampsia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singleton pregnancies.
  2. Women booked at our unit prior to 20 weeks' gestation.

Exclusion criteria

Exclusion Criteria:

  1. Multiple pregnancies.
  2. Age \< 16 years.
  3. Those unable to provide consent.
  4. Pregnancies with fetal abnormalities.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Unselected population

    Routine unselected populations at 20-22 weeks and 35-37 weeks

    Other: Umbilical cord measurements & observations

  • High risk population

    High-risk pregnancies attending the placental disorders clinic which have been deemed to be at risk of having adverse pregnancy outcomes.

    Other: Umbilical cord measurements & observations

Interventions

  • OtherUmbilical cord measurements & observations

    In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements: 1. Umbilical cord coiling index (UCI) 2. Transverse diameter of umbilical cord (UC) 3. Transverse diameter of umbilical vein (UV) and artery (UA) 4. Umbilical vein (UV) Doppler flow characteristics 5. Presence of nuchal cord

06

What researchers measure

Primary outcomes

  1. Delivery of small for gestational age (SGA) neonate

    Birth weight below the 5th and 10th percentile

    Time frame: 2 years

  2. Emergency CS for fetal distress

    Caesarean section carried out for fetal heart rate abnormalities in labour

    Time frame: 2 years

  3. Hypoxic ischaemic encephalopathy

    Brain damage in neonates causes due to lack of oxygen and confirmed on ultrasound scan

    Time frame: 2 years

  4. Stillbirth

    Death of a fetuses between 24 weeks and before the birth of the baby

    Time frame: 2 years

  5. Composite hypoxic morbidity

    A composite outcome measures of any of the above outcome measures

    Time frame: 2 years

Secondary outcomes

  1. Preterm delivery < 37 weeks

    Spontaneous and iatrogenic preterm delivery

    Time frame: 2 years

  2. Development of preeclampsia

    High blood pressure developing in pregnancy based on ISSHP criteria

    Time frame: 2 years

  3. Admission to neonatal intensive care unit

    Admission to intensive or high-dependency care

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hegazy AA. Anatomy and embryology of umbilicus in newborns: a review and clinical correlations. Front Med. 2016 Sep;10(3):271-7. doi: 10.1007/s11684-016-0457-8. Epub 2016 Sep 7. PubMed 27473223 ↗
  • Moshiri M, Zaidi SF, Robinson TJ, Bhargava P, Siebert JR, Dubinsky TJ, Katz DS. Comprehensive imaging review of abnormalities of the umbilical cord. Radiographics. 2014 Jan-Feb;34(1):179-96. doi: 10.1148/rg.341125127. PubMed 24428290 ↗
  • Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, Helwig B, Beerenstrauch M, Abou-Easa K, Hildreth T, Troyer D, Medicetty S. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells. 2003;21(1):50-60. doi: 10.1634/stemcells.21-1-50. Erratum In: Stem Cells. 2003;21(2):247. PubMed 12529551 ↗
  • Pacora P, Romero R, Jaiman S, Erez O, Bhatti G, Panaitescu B, Benshalom-Tirosh N, Jung EJ, Hsu CD, Hassan SS, Yeo L, Kadar N. Mechanisms of death in structurally normal stillbirths. J Perinat Med. 2019 Feb 25;47(2):222-240. doi: 10.1515/jpm-2018-0216. PubMed 30231013 ↗
  • Man J, Hutchinson JC, Heazell AE, Ashworth M, Jeffrey I, Sebire NJ. Stillbirth and intrauterine fetal death: role of routine histopathological placental findings to determine cause of death. Ultrasound Obstet Gynecol. 2016 Nov;48(5):579-584. doi: 10.1002/uog.16019. Epub 2016 Oct 25. PubMed 27781319 ↗
  • Ashoor G, Syngelaki A, Papastefanou I, Nicolaides KH, Akolekar R. Development and validation of model for prediction of placental dysfunction-related stillbirth from maternal factors, fetal weight and uterine artery Doppler at mid-gestation. Ultrasound Obstet Gynecol. 2022 Jan;59(1):61-68. doi: 10.1002/uog.24795. PubMed 34643306 ↗
  • Hammad IA, Blue NR, Allshouse AA, Silver RM, Gibbins KJ, Page JM, Goldenberg RL, Reddy UM, Saade GR, Dudley DJ, Thorsten VR, Conway DL, Pinar H, Pysher TJ; NICHD Stillbirth Collaborative Research Network Group. Umbilical Cord Abnormalities and Stillbirth. Obstet Gynecol. 2020 Mar;135(3):644-652. doi: 10.1097/AOG.0000000000003676. PubMed 32028503 ↗
  • Akolekar R, Tokunaka M, Ortega N, Syngelaki A, Nicolaides KH. Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks. Ultrasound Obstet Gynecol. 2016 Nov;48(5):624-630. doi: 10.1002/uog.17295. PubMed 27854387 ↗
  • Tantbirojn P, Saleemuddin A, Sirois K, Crum CP, Boyd TK, Tworoger S, Parast MM. Gross abnormalities of the umbilical cord: related placental histology and clinical significance. Placenta. 2009 Dec;30(12):1083-8. doi: 10.1016/j.placenta.2009.09.005. Epub 2009 Oct 22. PubMed 19853300 ↗
  • Jessop FA, Lees CC, Pathak S, Hook CE, Sebire NJ. Umbilical cord coiling: clinical outcomes in an unselected population and systematic review. Virchows Arch. 2014 Jan;464(1):105-12. doi: 10.1007/s00428-013-1513-2. Epub 2013 Nov 21. PubMed 24259031 ↗
  • Damasceno EB, de Lima PP. Wharton's jelly absence: a possible cause of stillbirth. Autops Case Rep. 2013 Dec 31;3(4):43-47. doi: 10.4322/acr.2013.038. eCollection 2013 Oct-Dec. PubMed 28584806 ↗
  • de Laat MW, Franx A, van Alderen ED, Nikkels PG, Visser GH. The umbilical coiling index, a review of the literature. J Matern Fetal Neonatal Med. 2005 Feb;17(2):93-100. doi: 10.1080/14767050400028899. PubMed 16076615 ↗
  • de Laat MW, van Alderen ED, Franx A, Visser GH, Bots ML, Nikkels PG. The umbilical coiling index in complicated pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007 Jan;130(1):66-72. doi: 10.1016/j.ejogrb.2006.01.018. Epub 2006 Mar 2. PubMed 16513244 ↗
  • Strong TH Jr, Jarles DL, Vega JS, Feldman DB. The umbilical coiling index. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):29-32. PubMed 8296839 ↗
  • De Laat MW, Franx A, Nikkels PG, Visser GH. Prenatal ultrasonographic prediction of the umbilical coiling index at birth and adverse pregnancy outcome. Ultrasound Obstet Gynecol. 2006 Oct;28(5):704-9. doi: 10.1002/uog.2786. PubMed 16952204 ↗
  • El Behery MM, Nouh AA, Alanwar AM, Diab AE. Effect of umbilical vein blood flow on perinatal outcome of fetuses with lean and/or hypo-coiled umbilical cord. Arch Gynecol Obstet. 2011 Jan;283(1):53-8. doi: 10.1007/s00404-009-1272-0. Epub 2009 Nov 7. PubMed 19898858 ↗
  • Degani S, Leibovich Z, Shapiro I, Gonen R, Ohel G. Early second-trimester low umbilical coiling index predicts small-for-gestational-age fetuses. J Ultrasound Med. 2001 Nov;20(11):1183-8. doi: 10.7863/jum.2001.20.11.1183. PubMed 11758023 ↗
  • Jo YS, Jang DK, Lee G. The sonographic umbilical cord coiling in late second trimester of gestation and perinatal outcomes. Int J Med Sci. 2011;8(7):594-8. doi: 10.7150/ijms.8.594. Epub 2011 Oct 7. PubMed 22022212 ↗
  • Sharma B, Bhardwaj N, Gupta S, Gupta PK, Verma A, Malviya K. Association of umbilical coiling index by colour Doppler ultrasonography at 18-22 weeks of gestation and perinatal outcome. J Obstet Gynaecol India. 2012 Dec;62(6):650-4. doi: 10.1007/s13224-012-0230-0. Epub 2012 Aug 17. PubMed 24293842 ↗
  • Mittal A, Nanda S, Sen J. Antenatal umbilical coiling index as a predictor of perinatal outcome. Arch Gynecol Obstet. 2015 Apr;291(4):763-8. doi: 10.1007/s00404-014-3456-5. Epub 2014 Sep 11. PubMed 25209352 ↗
  • Kosus A, Kosus N, Turhan NO. Is there any relation between umbilical artery and vein diameter and estimated fetal weight in healthy pregnant women? J Med Ultrason (2001). 2012 Oct;39(4):227-34. doi: 10.1007/s10396-012-0360-0. Epub 2012 May 9. PubMed 27279109 ↗
  • Tutus S, Asal N, Uysal G, Sahin H. Is there a relationship between high birth weight and umbilical vein diameter? J Matern Fetal Neonatal Med. 2021 Nov;34(21):3609-3613. doi: 10.1080/14767058.2020.1814247. Epub 2020 Oct 20. PubMed 33081536 ↗
  • Di Naro E, Raio L, Ghezzi F, Franchi M, Romano F, Addario VD. Longitudinal umbilical vein blood flow changes in normal and growth-retarded fetuses. Acta Obstet Gynecol Scand. 2002 Jun;81(6):527-33. PubMed 12047306 ↗
  • Clapp JF 3rd, Stepanchak W, Hashimoto K, Ehrenberg H, Lopez B. The natural history of antenatal nuchal cords. Am J Obstet Gynecol. 2003 Aug;189(2):488-93. doi: 10.1067/s0002-9378(03)00371-5. PubMed 14520223 ↗
  • Hayes DJL, Warland J, Parast MM, Bendon RW, Hasegawa J, Banks J, Clapham L, Heazell AEP. Umbilical cord characteristics and their association with adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One. 2020 Sep 24;15(9):e0239630. doi: 10.1371/journal.pone.0239630. eCollection 2020. PubMed 32970750 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jul 2025, 21 months after the start.

Of 46 non-industry observational studies under Hypoxia-Ischemia, Brain, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 20. This study's planned 21 months is below that.

Counting every sponsor, half of 50 studies reached it within 43 months; a quarter within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 13, 2023
StartActual
Oct 3, 2023
Primary completionEst.
Jul 3, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05901688
Lead sponsor
Medway NHS Foundation Trust
Responsible party
Professor Ranjit Akolekar (Consultant in Fetal Medicine & Obstetrics, Medway NHS Foundation Trust) — Principal investigator
First posted
Jun 13, 2023
Start date
Oct 3, 2023
Primary completion
Jul 3, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 12, 2024

Study contacts

Ranjit Akolekar, MD MRCOG PhD
Contact
ranjit.akolekar@nhs.net
+44 7944052009
Tara Giacchino, MD MRCOG MCh
Contact
tara.giacchino@nhs.net
+44 7799453795
Ranjit Akolekar, MD MRCOG PhD
principal investigator · Medway NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion